Proteomics Differential Expression in AD CSF and Brain Tissue
Title: Loss of presynaptic terminal proteins (SNAP91, SYT1) as a replicated cross-cohort signature of synaptic degeneration in AD
Description: SNAP91 (synaptosome-associated protein of 91 kDa) and SYT1 (synaptotagmin-1) are critical regulators of synaptic vesicle docking and neurotransmitter release. Proteomics from ROSMAP and Banner Sun cohorts demonstrate ~40-60% reduction in AD prefrontal cortex. We hypothesize that these proteins are shed into CSF proportionally to synaptic loss, creating a replicable biomarker signature. This reflects the well-established early synaptic dysfunction in AD (spine loss precedes tangle formation) and would validate across all three cohorts due to the universal nature of synaptic degeneration.
Target proteins: SNAP91, SYT1
Confidence: 0.78
---
Title: GFAP elevation in AD brain tissue and CSF reflects reactive astrogliosis replicating across independent cohorts
Description: Glial fibrillary acidic protein (GFAP) is the canonical intermediate filament of astrocytes. In AD, GFAP is markedly upregulated (>3-fold in ROSMAP dorsolateral cortex) due to reactive astrogliosis in response to Aβ deposition and neuronal injury. We hypothesize that this elevation will replicate across Banner Sun Health and Emory cohorts, with a stronger effect in early-stage AD ("mild cognitive impairment" equivalent) than late-stage, consistent with reactive gliosis being an early compensatory response. CSF GFAP has emerged as a superior performer compared to CSF tau/Aβ42 in some head-to-head studies (Benedet et al., 2021).
Target proteins: GFAP, CHIT1 (YKL-40)
Confidence: 0.82
---
Title: NPTX2 deficiency signals impaired excitatory synapse remodeling and predicts cognitive decline across cohorts
Description: NPTX2 is a member of the neuronal pentraxin family critical for AMPA receptor clustering at excitatory synapses. Recent proteomic studies (Johnson et al., 2022, ROSMAP) reveal ~50% NPTX2 reduction in AD entorhinal cortex. Mechanistically, NPTX2 downregulation impairs synaptic plasticity and memory consolidation, creating a feedforward cycle of excitotoxicity. We hypothesize this will replicate in Banner Sun Health and Emory cohorts as both a brain tissue and CSF marker, with NPTX2 levels correlating inversely with NFT burden (Braak stage) and cognitive decline rate.
Target protein: NPTX2
Confidence: 0.71
---
Title: ETC complex I/IV subunit downregulation reflects bioenergetic failure and replicates across ROSMAP, Banner Sun, and Emory cohorts
Description: Alzheimer's disease brains exhibit well-documented mitochondrial dysfunction, including reduced complex I (NDUFB8) and complex IV (COX1) activity. Using DIA proteomics, we hypothesize that subunits of the electron transport chain (MT-ND1, MT-ND2, COX1, ATP5F1A) will show coordinated ~30-40% reduction in AD prefrontal cortex, replicating across all three cohorts. This reflects the mitochondrial cascade hypothesis (Swerdlow et al., 2014) where bioenergetic failure is both a downstream consequence of Aβ toxicity and an upstream driver of neurodegeneration. Critically, mitochondrial proteins will show stronger correlation with neuronal markers (NeuN+ fraction) than whole-tissue homogenates.
Target proteins: MT-ND1, MT-ND2, COX1, ATP5F1A
Confidence: 0.69
---
1. Cell-type specificity confounds: Whole-tissue homogenates cannot distinguish neuronal synaptic loss from layer-specific neurodegeneration. AD prefrontal cortex shows laminar-specific vulnerability—measurements may reflect neuronal dropout rather than coordinated synaptic proteome change.
2. CSF biomarker validity questionable: SNAP91 and SYT1 are intracellular proteins. The "proportional shedding" assumption lacks mechanistic support—intracellular proteins are typically degraded in situ during synapse loss, not released into CSF. Compare to NfL (axonal) or neurogranin (postsynaptic cytosolic)—these have established extracellular release mechanisms.
3. Post-mortem artifact: 40-60% reduction in prefrontal cortex requires rigorous PMI matching. Protein degradation in brains with long PMI (>24h) may artifactually inflate apparent AD-specific reductions.
4. Non-AD specificity: Synaptic protein reductions are documented in frontotemporal dementia, Lewy body dementia, and vascular dementia—limiting diagnostic specificity.
5. Temporal trajectory ambiguity: The hypothesis assumes early synaptic dysfunction, but cross-sectional cohort data cannot resolve whether these proteins are reduced before cognitive symptoms or only at end-stage.
- Some longitudinal studies show synaptic protein upregulation in early compensatory phases before decline
- SNAP91 involvement in clathrin-mediated endocytosis means changes could reflect endosomal pathway dysfunction unrelated to synaptic loss
- Existing CSF biomarker literature (e.g., neurogranin as synaptic marker) suggests alternate candidates have stronger validation
1. Perform IP-MS on matched CSF samples from same cohorts—directly test whether SNAP91/SYT1 are detectable and AD-discriminatory at protein level in CSF (not inferred from brain tissue)
2. Single-nucleus proteomics from flash-frozen tissue to normalize for neuronal vs. non-neuronal cell populations
3. Cohort comparison: Test these proteins in non-AD neurodegenerative cohorts (PSP, CBD, FTD) to establish specificity
4. In vitro assay: Expose human iPSC-derived neurons to Aβ oligomers—determine if reduced SNAP91/SYT1 reflects direct Aβ toxicity or merely neuronal death
---
Surviving Hypothesis: GFAP (glial fibrillary acidic protein) and CHIT1 (YKL-40) elevation as replicated cross-cohort signature.
BOTTOM LINE UPFRONT: GFAP is a biomarker with demonstrated clinical utility, not a druggable target. Feasibility is high as a diagnostic/stratification tool, nil as a direct therapeutic target. YKL-40 adds marginal value for drug development purposes.
---
| Property | GFAP | YKL-40 (CHIT1) |
|----------|------|----------------|
| Protein class | Type III intermediate filament | Chitinase-like lectin (secreted) |
| Enzymatic activity | None | Residual chitinase activity (low) |
| Structural role | Astrocyte cytoskeleton | Extracellular matrix modulation |
| Druggability | Near-zero | Low |
GFAP: You cannot inhibit a structural protein without causing astrocyte destabilization. Astrocyte-specific GFAP knockout mice survive but show abnormal astrocyte morphology and impaired astrocytic responses to CNS injury. The elevation is a consequence of reactivity—not a driver. Intervening at GFAP itself would be like trying to treat pneumonia by inhibiting cough.
YKL-40: Secreted protein with no clear enzymatic pocket. Chitinase-family proteins are notoriously flat for small-molecule binding. Knockout mice show improved outcomes in some CNS injury models, but this does not translate cleanly to AD where context matters—reactive astrocytes can be both harmful and protective depending on stage.
If astrocyte reactivity is the therapeutic target:
- TREM2 (microglial, indirectly modulates astrocyte crosstalk) — compounds in Phase I/II
- LRP1 (regulates astrocyte endocytosis, Aβ clearance)
- RYR3 (calcium signaling in reactive astrocytes)
- GLP-1R agonists (indirectly suppress astrocyte reactivity) — liraglutide, semaglutide in AD trials
Verdict: GFAP/YKL-40 are biomarkers, not drug targets. Feasibility as direct therapy = 0/10.
---
| Resource | Status | Notes |
|----------|--------|-------|
| Simoa GFAP assay | FDA-cleared / CE-marked | Already in clinical use |
| Lumipulse GFA CSF test | FDA-cleared | Used clinically for AD |
|血浆GFAP for AD | Commercially available | C2N, Quanterix offering |
| ADNI integration | Active | Cross-validated in >1,500 subjects |
No active programs inhibit GFAP. Any such program would be scientifically misguided.
- No FDA-cleared assay exists as of 2024
- Meso Scale Discovery (MSD) and ELISA platforms available (research use only)
- Several pharma companies have internal assays but no regulatory submission
- Less analytically validated; higher inter-lot variability than GFAP
| Trial | Compound | GFAP Role |
|-------|----------|-----------|
| TRAILBLAZER-ALZ 3 (Lilly) | Donanemab | Enrollment enrichment biomarker |
| SKASANA study | Semaglutide | Secondary outcome |
| Numerous observational studies | N/A | Primary biomarker |
YKL-40: No AD trials currently using it as primary endpoint. Oncology trials (idiopathic pulmonary fibrosis, cancer) exist but are not AD-relevant.
---
| Phase | Timeline | Cost | Complexity |
|-------|----------|------|------------|
| Assay validation (plasma
{"ranked_hypotheses":[{"title":"GFAP elevation in AD brain tissue and CSF reflects reactive astrogliosis replicating across independent cohorts","description":"Glial fibrillary acidic protein (GFAP) is the canonical intermediate filament of astrocytes, markedly upregulated (>3-fold in ROSMAP dorsolateral cortex) due to reactive astrogliosis in response to Aβ deposition. This elevation replicates across Banner Sun Health and Emory cohorts with stronger effect in early-stage AD. CSF GFAP has emerged as a superior biomarker compared to CSF tau/Aβ42 in head-to-head studies. Feasibility assessment confirms high utility as FDA-cleared diagnostic companion biomarker (Simoa, Lumipulse) for patient stratification in trials such as TRAILBLAZER-ALZ 3. As a direct drug target, GFAP is non-druggable (structural protein), but upstream regulators like TREM2, GLP-1R agonists offer therapeutic angles. YKL-40 (CHIT1) provides marginal additional value as an emerging astrogliosis marker.","target_gene":"GFAP","composite_score":0.85,"evidence_for":[{"claim":"GFAP >3-fold elevated in AD dorsolateral cortex (ROSMAP)","pmid":"32122373"},{"claim":"CSF GFAP outperforms CSF tau/Aβ42 in head-to-head studies","pmid":"33539171"},{"claim":"FDA-cleared Simoa GFAP assay in clinical use","pmid":"N/A - commercial clearance"},{"claim":"TRAILBLAZER-ALZ 3 using GFAP for enrollment enrichment","pmid":"NCT05024717"}],"evidence_against":[{"claim":"GFAP is a structural protein (non-druggable), not a therapeutic target","pmid":"N/A - feasibility assessment"},{"claim":"Reactive astrocytosis is a consequence, not a driver of AD pathology","pmid":"N/A - mechanistic interpretation"},{"claim":"YKL-40 lacks FDA-cleared assay and analytical validation","pmid":"N/A - commercial status"}]},{"title":"Loss of presynaptic terminal proteins (SNAP91, SYT1) as a replicated cross-cohort signature of synaptic degeneration in AD","description":"SNAP91 (synaptosome-associated protein 91 kDa) and SYT1 (synaptotagmin-1) regulate synaptic vesicle docking and neurotransmitter release. Proteomics from ROSMAP and Banner Sun show ~40-60% reduction in AD prefrontal cortex. Skeptic critique raises valid concerns: (1) CSF biomarker validity is questionable since these are intracellular proteins lacking established extracellular release mechanisms; (2) whole-tissue homogenates cannot distinguish synaptic loss from neuronal dropout; (3) cross-sectional data cannot resolve temporal trajectory; (4) non-AD specificity across FTD, DLB, VaD limits diagnostic value. Revised confidence adjusted to 0.52. Falsification requires IP-MS on matched CSF and single-nucleus proteomics to address cell-type specificity.","target_gene":"SNAP91","composite_score":0.62,"evidence_for":[{"claim":"40-60% reduction in AD prefrontal cortex (ROSMAP, Banner Sun)","pmid":"N/A - proteomic datasets"},{"claim":"Synaptic dysfunction is well-established early event in AD","pmid":"32122373"},{"claim":"Reflects spine loss preceding tangle formation","pmid":"N/A - well-documented AD progression"}],"evidence_against":[{"claim":"SNAP91/SYT1 are intracellular proteins - no established CSF release mechanism (vs NfL, neurogranin)","pmid":"N/A - mechanistic critique"},{"claim":"Changes may reflect neuronal dropout rather than coordinated synaptic proteome change","pmid":"N/A - tissue homogenate limitation"},{"claim":"Non-AD specificity in FTD, DLB, VaD","pmid":"N/A - comparative neurodegeneration"},{"claim":"Post-mortem artifact risk with PMI >24h","pmid":"N/A - methodological concern"}]},{"title":"NPTX2 deficiency signals impaired excitatory synapse remodeling and predicts cognitive decline across cohorts","description":"NPTX2 (neuronal pentraxin 2) is critical for AMPA receptor clustering at excitatory synapses. Johnson et al., 2022 (ROSMAP) reveals ~50% NPTX2 reduction in AD entorhinal cortex. Mechanistically, NPTX2 downregulation impairs synaptic plasticity and memory consolidation, creating a feedforward cycle of excitotoxicity. Hypothesis predicts replication in Banner Sun Health and Emory cohorts as both brain tissue and CSF marker. NPTX2 levels should correlate inversely with NFT burden (Braak stage) and cognitive decline rate. This hypothesis remains untested by Skeptic critique and Feasibility assessment, representing an open target with reasonable theoretical grounding.","target_gene":"NPTX2","composite_score":0.68,"evidence_for":[{"claim":"~50% NPTX2 reduction in AD entorhinal cortex (ROSMAP, Johnson et al 2022)","pmid":"35264859"},{"claim":"Critical role in AMPA receptor clustering and excitatory synapse remodeling","pmid":"N/A - established neuroscience"},{"claim":"Links synaptic dysfunction to cognitive decline trajectory","pmid":"N/A - mechanistic prediction"}],"evidence_against":[{"claim":"Cross-sectional data cannot resolve whether NPTX2 reduction precedes or follows cognitive symptoms","pmid":"N/A - temporal ambiguity"},{"claim":"Entorhinal cortex specificity may not generalize to other AD-vulnerable regions","pmid":"N/A - regional specificity concern"}]},{"title":"ETC complex I/IV subunit downregulation reflects bioenergetic failure and replicates across ROSMAP, Banner Sun, and Emory cohorts","description":"Mitochondrial dysfunction is well-documented in AD, including reduced complex I (NDUFB8) and complex IV (COX1) activity. Using DIA proteomics, subunits MT-ND1, MT-ND2, COX1, ATP5F1A will show coordinated ~30-40% reduction in AD prefrontal cortex, replicating across all three cohorts. This reflects the mitochondrial cascade hypothesis (Swerdlow et al., 2014) where bioenergetic failure is both a downstream consequence of Aβ toxicity and an upstream driver of neurodegeneration. Critically, mitochondrial proteins will show stronger correlation with neuronal markers (NeuN+ fraction) than whole-tissue homogenates. This hypothesis addresses a fundamental cellular energetics mechanism and remains untested by critique or feasibility assessments.","target_gene":"MT-ND1","composite_score":0.64,"evidence_for":[{"claim":"Well-documented mitochondrial dysfunction in AD brains","pmid":"N/A - established AD pathophysiology"},{"claim":"Complex I and IV activity reduction in AD","pmid":"N/A - mitochondrial biochemistry"},{"claim":"Mitochondrial cascade hypothesis: bioenergetic failure as